https://www.selleckchem.com/pr....oducts/ly-411575.htm
In patients with high risk of bleeds or receiving thrombolysis, or when cost or specific patient issues exist, clopidogrel is considered though is a second-line therapy. Due to an elevated risk of bleeds, triple therapy should be avoided, as evidence shows effectiveness and safety with regimens without ASA. Furthermore, multiple studies have also shown that regimens shorter than 12 months of DAPT could be adequate for many patients, and newer guidelines are likely going to reflect it. There are specific recommendations for switching a
Tycka om
Kommentar
Dela med sig
